论文部分内容阅读
β受体阻滞剂为治疗心力衰竭的指南所推荐的一线首选药物之一。新近的相关研究证实,选用β受体阻滞剂治疗难治性心力衰竭与其预后改善明显相关,但其治疗心力衰竭时往往不伴心房颤动。因此迄今关于选用β受体阻滞剂治疗心力衰竭时,其与伴与不伴心房颤动患者继发心血管病不良预后间关系尚不清楚,现就此进行大样本随访相关分析。
Beta-blockers are one of the first-line preferred drugs recommended by the guidelines for the treatment of heart failure. Recent studies have confirmed that the use of β-blocker therapy for refractory heart failure and its prognosis were significantly related, but the treatment of heart failure is often not associated with atrial fibrillation. So far on the choice of β-blockers in the treatment of heart failure, its with and without atrial fibrillation in patients with secondary adverse cardiovascular disease prognosis is unclear, are large sample follow-up analysis.